Curasight A/S reports positive preclinical results with uTREAT® in aggressive brain cancer (glioblastoma)

Posted on by

Preclinical studies show uTREAT® efffective in treating aggressive brain cancer Data supports strategy to move uTREAT® into clinical development for evaluation in patients with aggressive brain cancer COPENHAGEN, Denmark, June 7, 2023 /PRNewswire/ — Curasight A/S (“Curasight” or “the…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.